RxDoctor Payments Data

Wade Muncey, MD

Urology · Meridian, IDNPI 1619408838

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,542 of the $8,957 with a category attached, or 73.0%. 24 manufacturers reported payments, led by Boston Scientific at 35.8% of the total. Among urology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,957in general payments, 2019–2025

Across 170 payments — averaging $52.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Coloplast$3K
  • Endo USA, Inc.$429
  • AbbVie$419
  • Endo Pharmaceuticals Inc.$362
  • Accord Healthcare, Inc.$222
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$2,41527%
  • Food & beverage$6,54273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,957 in reported general payments places this provider in the 95th percentile of 55 urology providers in Idaho.

See all urology providers in Idaho

Medicare billing

Part B allowed, 2024
$293,705
Medicare patients
234
Services billed
6,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron15$8,185
Cabergoline28$5,126
Testosterone Cypionate21$1,726
Testosterone22$1,625
Tamsulosin Hcl165$1,553
Alfuzosin Hcl ErAlfuzosin Hcl30$798
Fesoterodine Fumarate ErFesoterodine Fumarate21$565
Pentoxifylline40$491
Finasteride17$252
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$147
Oxycodone Hcl18$72
Tadalafil11$65
Meloxicam13$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$25$8,18515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 urology providers in Idaho.

Other urology in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →